Gut microbiota and cardiovascular disease
By M. Witkowski, Taylor L. Weeks, S. Hazen. Circulation Research, 2020
784 citations recorded by the source corpus.
Fecal microbial community changes are associated with numerous disease states, including cardiovascular disease (CVD). However, such data are merely associative. A causal contribution for gut microbiota in CVD has been further supported by a multitude of more direct experimental evidence. Indeed, gut microbiota transplantation studies, specific gut microbiota–dependent pathways, and downstream metabolites have all been shown to influence host metabolism and CVD, sometimes through specific identified host receptors. Multiple metaorganismal pathways (involving both microbe and host) both impact CVD in animal models and show striking clinical associations in human studies. For example, trimethylamine N-oxide and, more recently, phenylacetylglutamine are gut microbiota–dependent metabolites whose blood levels are associated with incident CVD risks in large-scale clinical studies. Importantly, a causal link to CVD for these and other specific gut microbial metabolites/pathways has been shown through numerous mechanistic animal model studies. Phenylacetylglutamine, for example, was recently shown to promote adverse cardiovascular phenotypes in the host via interaction with multiple ARs (adrenergic receptors)—a class of key receptors that regulate cardiovascular homeostasis. In this review, we summarize recent advances of microbiome research in CVD and related cardiometabolic phenotypes that have helped to move the field forward from associative to causative results. We focus on microbiota and metaorganismal compounds/pathways, with specific attention paid to short-chain fatty acids, secondary bile acids, trimethylamine N-oxide, and phenylacetylglutamine. We also discuss novel therapeutic strategies for directly targeting the gut microbiome to improve cardiovascular outcomes.
Subfields: Infectious Diseases, Molecular Biology, Physiology
View Paper: https://www.semanticscholar.org/paper/6154383f1a97fbdec3ea3b1045d2c52540b8643a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Molecular Biology
In Physiology
Citations in the corpus
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications (2024, background): “75 The importance of low-grade inflammation in CVD has been highlighted in a recent study by Ridker et al , demonstrating by analysing three large multinational trials of patients receiving statin therapy that low-grade inflammation as measured by plasma high-sensitivity C reactive protein (hsCRP)…”